Viridian Therapeutics (VRDN) News Today $18.38 -0.06 (-0.33%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$18.40 +0.02 (+0.08%) As of 08/29/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRDN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Analysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) Price Target at $37.78August 31 at 2:48 AM | americanbankingnews.com248,628 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Nuveen LLCAugust 30 at 3:41 AM | marketbeat.comAffinity Asset Advisors LLC Has $5.26 Million Stock Holdings in Viridian Therapeutics, Inc. $VRDNAugust 28 at 9:02 AM | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of "Moderate Buy" from BrokeragesAugust 28 at 5:21 AM | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Now Covered by Analysts at Jefferies Financial GroupAugust 27, 2025 | marketbeat.com13,742 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by EntryPoint Capital LLCAugust 27, 2025 | marketbeat.comRussell Investments Group Ltd. Sells 181,338 Shares of Viridian Therapeutics, Inc. $VRDNAugust 27, 2025 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Coverage Initiated at Jefferies Financial GroupAugust 27, 2025 | americanbankingnews.comAlgert Global LLC Sells 50,850 Shares of Viridian Therapeutics, Inc. $VRDNAugust 26, 2025 | marketbeat.comViridian Therapeutics, Inc. $VRDN Stake Cut by Vanguard Group Inc.August 26, 2025 | marketbeat.comViridian Therapeutics, Inc. $VRDN Shares Purchased by Candriam S.C.A.August 24, 2025 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) & Y-mAbs Therapeutics (NASDAQ:YMAB) Critical AnalysisAugust 21, 2025 | americanbankingnews.comHC Wainwright Issues Optimistic Estimate for VRDN EarningsAugust 11, 2025 | marketbeat.comLeerink Partnrs Issues Optimistic Outlook for VRDN EarningsAugust 11, 2025 | marketbeat.comLifesci Capital Has Negative Estimate for VRDN Q3 EarningsAugust 11, 2025 | marketbeat.comWedbush Research Analysts Boost Earnings Estimates for VRDNAugust 11, 2025 | marketbeat.comWedbush Lowers Earnings Estimates for Viridian TherapeuticsAugust 9, 2025 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Posts Earnings Results, Hits ExpectationsAugust 9, 2025 | marketbeat.comThe Goldman Sachs Group Issues Positive Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock PriceAugust 8, 2025 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Price Target Lowered to $41.00 at Royal Bank Of CanadaAugust 8, 2025 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Price Target Lowered to $26.00 at Wells Fargo & CompanyAugust 8, 2025 | marketbeat.comOppenheimer Increases Viridian Therapeutics (NASDAQ:VRDN) Price Target to $32.00August 8, 2025 | marketbeat.comNeedham & Company LLC Cuts Viridian Therapeutics (NASDAQ:VRDN) Price Target to $34.00August 7, 2025 | marketbeat.comThese Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 ResultsAugust 7, 2025 | benzinga.comViridian Therapeutics (VRDN) to Release Earnings on ThursdayAugust 7, 2025 | marketbeat.comViridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial ResultsAugust 6, 2025 | finance.yahoo.comViridian Therapeutics (NASDAQ:VRDN) Stock Price Down 3.5% - Here's What HappenedAugust 5, 2025 | marketbeat.comJ. Safra Sarasin Holding AG Has $980,000 Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)August 5, 2025 | marketbeat.comTD Asset Management Inc Trims Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)August 5, 2025 | marketbeat.comBIT Capital GmbH Has $966,000 Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)August 4, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by DCF Advisers LLCAugust 4, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of "Moderate Buy" by BrokeragesAugust 2, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Short Interest UpdateAugust 2, 2025 | marketbeat.comViridian and Kissei to advance veligrotug and VRDN-003 in JapanAugust 1, 2025 | finance.yahoo.comViridian Therapeutics (NASDAQ:VRDN) Shares Gap Up - Still a Buy?July 31, 2025 | marketbeat.comViridian Therapeutics Shares Rise Premarket on Kissei License PactJuly 30, 2025 | marketwatch.comViridian partners with Japanese firm for Veligrotug and VRDN-003July 30, 2025 | msn.comViridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone PaymentsJuly 30, 2025 | businesswire.comVictory Capital Management Inc. Raises Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)July 26, 2025 | marketbeat.comPrincipal Financial Group Inc. Acquires 30,392 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)July 19, 2025 | marketbeat.comViridian Therapeutics’ Veligrotug Shows Durable Proptosis Response in Phase 3 TED TrialJuly 15, 2025 | msn.comRice Hall James & Associates LLC Acquires 309,518 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)July 14, 2025 | marketbeat.comViridian Therapeutics price target lowered to $38 from $41 at Evercore ISIJuly 11, 2025 | msn.comViridian Therapeutics Sees Relative Strength Rating Improve To 79July 10, 2025 | msn.comViridian Therapeutics (NASDAQ:VRDN) Trading Up 8.4% - Here's WhyJuly 9, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Rating of "Moderate Buy" from AnalystsJuly 7, 2025 | marketbeat.comViridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 3, 2025 | finance.yahoo.comViridian Therapeutics (NASDAQ:VRDN) Shares Down 4.5% - What's Next?June 17, 2025 | marketbeat.comViridian Therapeutics’ SWOT analysis: promising TED treatment stock faces pivotal yearJune 15, 2025 | investing.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Recommendation of "Moderate Buy" by AnalystsJune 12, 2025 | marketbeat.com Get Viridian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VRDN Media Mentions By Week VRDN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRDN News Sentiment▼1.331.11▲Average Medical News Sentiment VRDN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRDN Articles This Week▼125▲VRDN Articles Average Week Get the Latest News and Ratings for VRDN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Viridian Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies RDNT News Today SHC News Today OPCH News Today BTSG News Today NAKA News Today WGS News Today CON News Today SGRY News Today PRVA News Today VCYT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VRDN) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viridian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VRDN Stock Alerts